Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study
- 1 March 2015
- journal article
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 48, 328-336
Abstract
No abstract availableKeywords
Funding Information
- FIRB Futuro in Ricerca 2010 (RBFR10XKHS_002)
This publication has 51 references indexed in Scilit:
- Modulating the endocannabinoid system in human health and disease – successes and failuresThe FEBS Journal, 2013
- Novelty-Induced Emotional Arousal Modulates Cannabinoid Effects on Recognition Memory and Adrenocortical ActivityNeuropsychopharmacology, 2013
- The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD)Frontiers in Behavioral Neuroscience, 2013
- Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesPhilosophical Transactions of the Royal Society B: Biological Sciences, 2012
- Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent RatsJournal of Neuroscience, 2012
- Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacyJournal of Controlled Release, 2012
- Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosisExpert Opinion on Emerging Drugs, 2009
- The Endocannabinoid System as an Emerging Target of PharmacotherapyPharmacological Reviews, 2006
- CANNABINOID RECEPTORS AS THERAPEUTIC TARGETSAnnual Review of Pharmacology and Toxicology, 2006
- Inverse agonism and neutral antagonism at cannabinoid CB1 receptorsLife Sciences, 2005